Close X
Attorney Spotlight

Find out how Gardner Bell's experience promoting financial and economic development initiatives both locally and abroad informs his role as an attorney. Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Securities Law Exchange BlogSecurities Law Exchange blog offers insight on the latest legal and regulatory developments affecting publicly traded companies. It focuses on a wide variety of topics including regulation and reporting updates, public company advisory topics, IPO readiness and exchange updates including IPO announcements, M&A trends and deal news.

Read More >

Medico-Legal Ethics of Off-Label Use of Pharmaceuticals and Devices

Events

May 8, 2012

Bass, Berry & Sims healthcare attorneys John Kelly and Danielle Sloane will present the topic "Medico-Legal Ethics of Off-Label Use of Pharmaceuticals and Devices," at an upcoming Nashville Council of Health Care Attorneys (NCHCA) meeting. This presentation will include:

  • Overview of what constitutes off label use versus off label promotion and why physicians prescribe off-label;
  • Government recent enforcement of off-label promotion violations;
  • The pharmaceutical and device companies attempting to limit the FDA's reach with the first amendment;
  • FDA response to industry requests for additional clarity on when it is permissible for pharmaceutical and device companies to distribute information regarding off-label uses; and
  • An ethical debate and evaluation of competing interests: regulatory oversight versus off-label promotion and use.

This course has been approved for one hour of dual CLE credit.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.